The American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) has developed comprehensive guidelines for preventing and managing infections in regional anesthesia and pain management procedures. These guidelines, commissioned in 2020, address a critical need in the field, as approximately 50% of surgical site infections are preventable when proper infection control practices are followed.
A recent study examined the effects of combining the diabetes medication dapagliflozin with a calorie-restricted diet on achieving remission of type 2 diabetes. Conducted at 16 centers in China, the randomized, double-blind, placebo-controlled trial involved 328 patients with type 2 diabetes, aged 20-70, who were either overweight or obese. Participants received either dapagliflozin (10 mg/day) or a placebo with a 500-750 kcal/day diet.
Inventiva, a clinical-stage biopharmaceutical company, has announced promising results from the LEGEND trial, which evaluated the combination of lanifibranor and empagliflozin for treating metabolic dysfunction-associated steatohepatitis (MASH) in patients with type-2 diabetes (T2D). These findings will be presented during an oral plenary session at the upcoming EASL Steatotic Liver Disease (SLD) Summit 2025 in Portugal.
This study looked at how people who have had heart attacks understand their risk of getting diabetes. The researchers studied 466 heart attack patients in Augsburg, Germany, and found some concerning results.
This study analyzed the potential protective effects of metformin, a common diabetes medication, on non-melanoma skin cancers (NMSC) — basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) — using a large and diverse U.S. health database called All of Us. Skin cancer poses significant risks, particularly in patients with darker skin tones, due to delayed diagnosis and unique risk factors. For example, SCC in African American patients has a much higher metastasis risk (20-40%) compared to sun-induced SCCs in Caucasian populations (1-4%).
